WCA
CRL icon

Waratah Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Waratah Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,420
Closed -$5.06M – 161
2023
Q4 		$5.06M Sell
21,420
-47,839
-69% -$9.41M 0.1% 77
2023
Q3 		$13.6M Buy
69,259
+47,196
+214% +$9.69M 0.19% 64
2023
Q2 		$4.64M Sell
22,063
-4,224
-16% -$840K 0.09% 83
2023
Q1 		$5.31M Buy
26,287
+16,741
+175% +$3.79M 0.12% 89
2022
Q4 		$2.08M Sell
9,546
-2,521
-21% -$551K 0.03% 111
2022
Q3 		$2.38M Buy
12,067
+9,518
+373% +$2.05M 0.04% 116
2022
Q2 		$545K Buy
+2,549
New +$623K 0.01% 149
2021
Q4 		– Sell
-3,116
Closed -$1.29M – 255
2021
Q3 		$1.29M Buy
3,116
+974
+45% +$405K 0.02% 140
2021
Q2 		$792K Sell
2,142
-1,283
-37% -$428K 0.01% 159
2021
Q1 		$993K Buy
+3,425
New +$952K 0.02% 153

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Waratah Capital Advisors's CRL Position: Q1 2024 in Review

Waratah Capital Advisors sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 21,420 shares — an estimated $5.06M sold.

Waratah Capital Advisors first reported a position in CRL in Q1 2021 and held it in 10 quarters. The position peaked at $13.6M in Q3 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Waratah Capital Advisors reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Waratah Capital Advisors sold 21,420 Charles River Laboratories shares in Q1 2024, an estimated $5.06M.
  • Waratah Capital Advisors first reported a position in Charles River Laboratories in Q1 2021 and held it in 10 quarters.
  • Waratah Capital Advisors's Charles River Laboratories position peaked at $13.6M in Q3 2023.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Waratah Capital Advisors's 13F filing for Q1 2024, filed 14 May 2024.